LANLUMA® V

Key Uses of Lanluma V

Lanluma V is a versatile treatment for facial and body rejuvenation. Its primary indications include:

• Facial volumisation (cheeks, temples, jawline).
• Body contouring (buttocks, thighs, hands).
• Skin tightening and rejuvenation.
• Acne scar improvement.
• Cellulite reduction.
• Deep wrinkle smoothing.

Manufacturing Information for Lanluma V

Lanluma V is manufactured by Sinclair Pharma headquartered in London, UK, and specialises in collagen-stimulating injectables. 

Other products in the Lanluma range are:

• Lanluma X – A higher concentration version designed for enhanced body contouring and volume restoration.

Expected Benefits and Results of the Treatments

Lanluma V provides long-lasting aesthetic improvements through collagen stimulation. Key benefits include:

• Gradual volume restoration – Results develop over weeks as collagen production increases.
• Natural-looking enhancements – Unlike traditional fillers, Lanluma V ensures subtle, harmonious results.
• Improved skin elasticity – Stimulates fibroblasts for firmer skin.
• Reduction of wrinkles and fine lines – Smooths deep folds and improves skin texture.
• Long-lasting effects – Results can last up to two years.

Lanluma V Key Ingredients and Device Properties

Lanluma V is formulated with carefully selected ingredients to optimise collagen stimulation.

Key ingredients:

• Poly-L-lactic acid (PLLA): 210 mg – Stimulates fibroblast activity and collagen synthesis.
• Sodium carboxymethyl cellulose – Enhances formulation stability.
• Mannitol – Aids in uniform particle dispersion.

Device properties:

• Biodegradable – Naturally absorbed by the body over time.
• Non-toxic – Safe for medical use with minimal side effects.

Included Items or Accessories

Each Lanluma V package contains:

• 1 x 15ml vial of powder.
• Instruction for use.

Administration Method for Lanluma V

Medical professionals must follow strict protocols when preparing and administering Lanluma V.

Pre-procedure:

• Assess patient suitability and discuss treatment goals.
• Cleanse the treatment area with an antiseptic solution.

During procedure:

• Remove the vial’s tear-off cap and disinfect the stopper.
• Attach an 18G needle to a sterile syringe and add 15ml of sterile water to the powder.
• Shake vigorously for 10 minutes, then allow hydration for 1 hour.
• Shake again before use and inject within 72 hours.
• Administer subcutaneously or into the dermis.

• Massage the treated area post-injection for even distribution.

Post-procedure:

• Advise the patient to follow aftercare guidelines.
• Monitor for any adverse reactions.

Guidelines for Proper Aftercare

To optimise results and minimise risks, patients should:

• Massage the treated area five times a day for five days.
• Avoid strenuous exercise for 48 hours.
• Refrain from alcohol and smoking for 24 hours.
• Keep hydrated to support collagen production.
• Avoid excessive sun exposure and use SPF 50.

Duration of Lanluma V Effects

Results typically last 18 to 24 months. Maintenance treatments are recommended every 12-18 months to sustain collagen stimulation.

Potential Risks and Lanluma Side Effects

Lanluma V is well-tolerated. However, as with any injectable treatment, there are potential risks and side effects that patients should be aware of:

Common side effects

• Swelling and redness – Common at the injection site, typically subsiding within 48 hours.
• Bruising – This can occur due to needle insertion but fades within a few days.
• Tenderness and discomfort – Mild soreness at the treatment site, often lasting a few days.
• Itching and irritation – Some patients may experience slight itching as the skin adjusts.
• Firmness or small lumps – Can appear as collagen production begins but usually smooths out with massage.

Rare side effects

• Delayed-onset nodules – Small lumps or bumps under the skin that may develop weeks or months after treatment. Proper massage can reduce the risk.
• Asymmetry – Uneven results may occur if the product is not distributed properly, requiring correction.
• Allergic reactions – Extremely rare but may include rash, swelling, or difficulty breathing. Immediate medical care is required if symptoms occur.
• Inflammation or infection – Redness, warmth, or pus at the injection site may indicate an infection and should be evaluated by a healthcare provider.
• Granulomas – Hard nodules may form in rare cases due to an overactive immune response.
• Skin discolouration – Hyperpigmentation or lightening of the skin may occur in some individuals.

Lanluma V Treatment Contraindications

Certain individuals should avoid Lanluma V treatment:

• Pregnant or breastfeeding women – Safety has not been established for this group.
• Patients with active skin infections – Conditions like acne, dermatitis, or cold sores at the injection site can increase the risk of complications.
• Autoimmune disease patients – Those with lupus, rheumatoid arthritis, or other immune disorders may have unpredictable reactions.
• Individuals with a history of severe allergies – Patients with hypersensitivity to any of the ingredients should avoid treatment.
• Patients prone to keloid or hypertrophic scarring – The injection may trigger excessive scar formation.
• Those with bleeding disorders or on anticoagulant therapy – Increased risk of bruising, hematoma, or prolonged healing.
• People with a history of granuloma formation – There is a higher chance of nodules developing post-treatment.
• Patients with poorly controlled diabetes – Slower wound healing and increased risk of infection.
• Those with compromised immune systems – Individuals undergoing chemotherapy, taking immunosuppressants, or with chronic illnesses may have a higher risk of infection or poor healing.
• Patients with unrealistic expectations – Lanluma V provides gradual improvements, so those seeking immediate results may not be ideal candidates.
• Individuals with silicone or permanent fillers in the treatment area – Interaction with previous fillers may lead to complications.
• Anyone with a known hypersensitivity to poly-L-lactic acid (PLLA) or related ingredients – Patients allergic to PLLA should not receive the treatment.